IS7402A - New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IX - Google Patents
New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IXInfo
- Publication number
- IS7402A IS7402A IS7402A IS7402A IS7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A IS 7402 A IS7402 A IS 7402A
- Authority
- IS
- Iceland
- Prior art keywords
- producing
- calcium
- methods
- new
- forms
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 2
- 229960005370 atorvastatin Drugs 0.000 title 2
- 229910052791 calcium Inorganic materials 0.000 title 1
- 239000011575 calcium Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35718102P | 2002-02-15 | 2002-02-15 | |
| US42532502P | 2002-11-12 | 2002-11-12 | |
| PCT/US2003/005384 WO2003070702A1 (en) | 2002-02-15 | 2003-02-19 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7402A true IS7402A (en) | 2004-08-13 |
Family
ID=27760457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7402A IS7402A (en) | 2002-02-15 | 2004-08-13 | New crystalline forms of atorvastatin semi-calcium and methods for producing them, as well as new methods for producing atorvastatin semi-calcium forms I, VIII and IX |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1480950A4 (en) |
| JP (2) | JP2005519076A (en) |
| KR (1) | KR100724515B1 (en) |
| CN (1) | CN100406436C (en) |
| AU (1) | AU2003217653A1 (en) |
| CA (1) | CA2475864A1 (en) |
| DE (1) | DE03713610T1 (en) |
| ES (1) | ES2241507T1 (en) |
| HR (1) | HRP20040768A2 (en) |
| IS (1) | IS7402A (en) |
| MX (1) | MXPA04007939A (en) |
| NO (1) | NO20043842L (en) |
| PL (1) | PL372303A1 (en) |
| WO (1) | WO2003070702A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| MXPA04007995A (en) | 2002-02-19 | 2004-11-26 | Teva Pharma | Processes for desolvating solvates of atorvastatin hemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent. |
| EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| JP2008506764A (en) * | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | [R- (R *, R *)]-2- (4-fluorophenyl) -β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4-[(phenylamino) carbonyl]- Novel form of 1H-pyrrole-1-heptanoic acid calcium salt (2: 1) |
| JP2007505944A (en) * | 2004-07-22 | 2007-03-15 | テバ ファーマシューティカル インダストリーズ リミティド | Atorvastatin hemi-calcium and process for its preparation |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| WO2006106372A1 (en) * | 2005-04-08 | 2006-10-12 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | New crystalline atorvastatin hemicalcium salt polymorph form |
| WO2007057755A1 (en) | 2005-11-21 | 2007-05-24 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium |
| CA2633268A1 (en) * | 2005-12-13 | 2007-06-21 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| EP2132171A4 (en) * | 2007-03-02 | 2010-11-17 | Dong A Pharm Co Ltd | NOVEL CRYSTALLINE FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES |
| KR20120011249A (en) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | Novel crystalline forms of atorvastatin hemicalcium salts, hydrates thereof, and methods for preparing the same |
| KR101324862B1 (en) * | 2011-07-12 | 2013-11-01 | (주)에이에스텍 | Spherical particle of clopidogrel bisulfate, pharmaceutical composition comprising the same and method of preparation thereof |
| EP3578546A1 (en) | 2013-11-15 | 2019-12-11 | Akebia Therapeutics Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| CN105055357A (en) * | 2015-09-25 | 2015-11-18 | 青岛华之草医药科技有限公司 | Atorvastatin calcium composition tablet for treating hypercholesteremia |
| KR101723783B1 (en) * | 2017-02-24 | 2017-04-07 | 주식회사 경보제약 | Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100431038B1 (en) * | 1995-07-17 | 2004-05-12 | 워너-램버트 캄파니 엘엘씨 | Crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Atorvastatin) |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| CZ20021642A3 (en) * | 1999-11-17 | 2003-05-14 | Teva Pharmaceutical Industries Ltd. | Polymorphous forms of calcium atorvastatin |
| EP1237865B1 (en) * | 1999-12-17 | 2005-11-16 | Pfizer Science and Technology Ireland Limited | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
| WO2001044181A1 (en) * | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
| CZ20031495A3 (en) * | 2000-11-03 | 2004-01-14 | Teva Pharmaceutical Industries Ltd. | Hemi-calcium atorvastatin form VII |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| AU2002224952B2 (en) * | 2000-12-27 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SK16002003A3 (en) * | 2001-06-29 | 2004-12-01 | Warner-Lambert Company Llc | Crystalline Forms of Calcium Salt (2: 1) [R- (R *, R *)] - 2- (4-Fluoro-phenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H-pyrrole-1-heptanoic acid (atorvastatin) |
| RU2304139C2 (en) * | 2001-07-30 | 2007-08-10 | Д-р Редди'с Лабораторис Лтд | Crystalline forms vi and vii of atorvastatin calcium salt |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| US20060122403A1 (en) * | 2002-09-03 | 2006-06-08 | Sanjay Suri | Atorvastatin calcium form vi or hydrates thereof |
| EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
-
2003
- 2003-02-19 MX MXPA04007939A patent/MXPA04007939A/en unknown
- 2003-02-19 DE DE03713610T patent/DE03713610T1/en active Pending
- 2003-02-19 WO PCT/US2003/005384 patent/WO2003070702A1/en not_active Ceased
- 2003-02-19 JP JP2003569609A patent/JP2005519076A/en not_active Withdrawn
- 2003-02-19 ES ES03713610T patent/ES2241507T1/en active Pending
- 2003-02-19 KR KR1020047012591A patent/KR100724515B1/en not_active Expired - Fee Related
- 2003-02-19 AU AU2003217653A patent/AU2003217653A1/en not_active Abandoned
- 2003-02-19 EP EP03713610A patent/EP1480950A4/en not_active Withdrawn
- 2003-02-19 PL PL03372303A patent/PL372303A1/en not_active Application Discontinuation
- 2003-02-19 CN CNB038082071A patent/CN100406436C/en not_active Expired - Fee Related
- 2003-02-19 CA CA002475864A patent/CA2475864A1/en not_active Abandoned
- 2003-02-19 HR HR20040768A patent/HRP20040768A2/en not_active Application Discontinuation
-
2004
- 2004-08-13 IS IS7402A patent/IS7402A/en unknown
- 2004-09-14 NO NO20043842A patent/NO20043842L/en not_active Application Discontinuation
-
2009
- 2009-06-08 JP JP2009137400A patent/JP2009235083A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04007939A (en) | 2004-11-26 |
| WO2003070702A1 (en) | 2003-08-28 |
| HRP20040768A2 (en) | 2005-06-30 |
| EP1480950A1 (en) | 2004-12-01 |
| JP2005519076A (en) | 2005-06-30 |
| KR100724515B1 (en) | 2007-06-04 |
| EP1480950A4 (en) | 2005-05-18 |
| NO20043842L (en) | 2004-09-14 |
| ES2241507T1 (en) | 2005-11-01 |
| CN100406436C (en) | 2008-07-30 |
| CN1646490A (en) | 2005-07-27 |
| KR20040081202A (en) | 2004-09-20 |
| CA2475864A1 (en) | 2003-08-28 |
| DE03713610T1 (en) | 2005-10-20 |
| PL372303A1 (en) | 2005-07-11 |
| JP2009235083A (en) | 2009-10-15 |
| AU2003217653A1 (en) | 2003-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI20030241L (en) | Method for producing synthesis gas | |
| PT1398327E (en) | METHOD OF PRODUCTION OF HYDROXYALQUIL-AMIDO DERIVATIVES | |
| CY2015015I1 (en) | PRODUCTION OF THIACOMYCIN | |
| IS7261A (en) | N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and methods for producing them | |
| FI20022084L (en) | Method of making newsprint | |
| NO20034285D0 (en) | Process for producing synthesis gas | |
| IS7467A (en) | Lansoprazole multiple synthesis and methods of producing them | |
| IS7600A (en) | A method of promoting smoke | |
| NO20043842L (en) | New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX | |
| DK1518827T3 (en) | Crystallized IM-12 solid and process for its preparation | |
| IS8447A (en) | A method of producing gamma-carboxylated protein | |
| AU2003261191A8 (en) | Methods for producing biopolymers | |
| PL371629A1 (en) | Production method of combrestinates | |
| IS8416A (en) | Method of production of CCR-2 antagonist | |
| GB0211842D0 (en) | Method of voice authentication | |
| IS7069A (en) | Method of producing zaleplon | |
| DK1890570T3 (en) | Toothbrush head and method of manufacture thereof | |
| FI20031467L (en) | Method and arrangement for producing experiences | |
| EP1600511A4 (en) | Method of treating ischemic disease | |
| NO20043568L (en) | Method of Preparing Citalopram | |
| EP1592431A4 (en) | Method of modulating il-6 | |
| FI20031639A7 (en) | Method for producing somatic embryos of conifers | |
| FI20010892L (en) | Method for producing xylitol | |
| PL356895A1 (en) | Method of manufacture of n-(4-cyano-3-trifluoromethylo phenylo)-2,3-epoxy-2-methyl prop anamide | |
| ITMI20021432A0 (en) | METHOD FOR PRODUCING CEPHALOSPORINS |